Persistence of asthma following allergen avoidance is associated with proTh2 myeloid dendritic cell activation

Thorax

Volumn 70, Issue 10, 2015, Pages 967-973

  Froidure, Antoine ^a,b,c   Vandenplas, Olivier ^a,b,d   D'Alpaos, Vinciane ^d   Evrard, Geneviève ^d   Pilette, Charles ^a,b,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Welbio (Walloon Excellence in Lifesciences and Biotechnology)   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; GAMMA INTERFERON; HISTAMINE; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 5; LATEX; PROGRAMMED DEATH 1 LIGAND 2;

ADULT; ALLERGIC ASTHMA; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; FEMALE; FLOUR; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; LEUKAPHERESIS; MALE; MIDDLE AGED; MYELOID DENDRITIC CELL; OCCUPATIONAL ASTHMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH2 CELL; UPREGULATION; ASTHMA, OCCUPATIONAL; BONE MARROW CELL; DENDRITIC CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ALLERGENS; ASTHMA, OCCUPATIONAL; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FLOUR; HUMANS; INTERLEUKIN-13; INTERLEUKIN-5; LATEX; MYELOID CELLS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN;

EID: 84942109404     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206364     Document Type: Article

References (35)

1. Woodcock A, Forster L, Matthews E, et al. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med 2003;349:225-236.
2. Vandenplas O, Dressel H, Wilken D, et al. Management of occupational asthma: cessation or reduction of exposure? A systematic review of available evidence. Eur Respir J 2011;38:804-811.
3. Rachiotis G, Savani R, Brant A, et al. Outcome of occupational asthma after cessation of exposure: a systematic review. Thorax 2007;62:147-152.
4. Maghni K, Lemiere C, Ghezzo H, et al. Airway inflammation after cessation of exposure to agents causing occupational asthma. Am J Respir Crit Care Med 2004;169:367-372.
5. Piirila PL, Meuronen A, Majuri ML, et al. Inflammation and functional outcome in diisocyanate-induced asthma after cessation of exposure. Allergy 2008;63:583-591.
6. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet 2010;376:835-843.
7. Lombardi V, Singh AK, Akbari O. The role of costimulatory molecules in allergic disease and asthma. Int Arch Allergy Immunol 2010;151:179-89.
8. Lewkowich IP, Lajoie S, Stoffers SL, et al. PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production. Mucosal Immunol 2013;6:728-739.
9. Akbari O, Stock P, Singh AK, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol 2010;3:81-91.
10. Shen C, Hupin C, Froidure A, et al. Impaired ICOSL in human myeloid dendritic cells promotes Th2 responses in patients with allergic rhinitis and asthma. Clin Exp Allergy 2014;44:831-841.
11. Charbonnier AS.Der p 1-pulsed myeloid and plasmacytoid dendritic cells from house dust mite-sensitized allergic patients dysregulate the T cell response. J Leukoc Biol 2003;73:91-99.
12. Pilette C, Jacobson MR, Ratajczak C, et al. Aberrant dendritic cell function conditions Th2-cell polarization in allergic rhinitis. Allergy 2013;68:312-321.
13. Froidure A, Shen C, Gras D, et al. Myeloid dendritic cells are primed in allergic asthma for thymic stromal lymphopoietin-mediated induction of Th2 and Th9 responses. Allergy 2014;69:1068-1076.
14. [No authors listed]. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-1136.
15. Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:53-83.
16. Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005;202:1213-1223.
17. Cazzoletti L, Corsico AG, Albicini F, et al. The course of asthma in young adults: a population-based nine-year follow-up on asthma remission and control. PLoS ONE 2014;9:e86956.
18. Holm M, Omenaas E, Gislason T, et al. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J 2007;30:62-65.
19. Boulet LP, Turcotte H, Brochu A. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest 1994;105:1024-1031.
20. de Groene GJ, Pal TM, Beach J, et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev 2011;(5):CD006308.
21. Tai A, Tran H, Roberts M, et al. Outcomes of childhood asthma to the age of 50 years. J Allergy Clin Immunol 2014;133:1572.e3.-1578.e3.
22. Upham JW, James AL. Remission of asthma: the next therapeutic frontier? Pharmacol Ther 2011;130:38-45.
23. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475.
24. Boulet LP, Turcott H, Plante S, et al. Airway function, inflammation and regulatory T cell function in subjects in asthma remission. Can Respir J 2012;19:19-25.
25. Simpson TR, Quezada SA, Allison JP. Regulation of CD4T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol 2010;22:326-332.
26. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-242.
27. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
28. Oflazoglu E, Swart DA, Anders-Bartholo P, et al. Paradoxical role of programmed death-1 ligand 2 in Th2 immune responses in vitro and in a mouse asthma model in vivo. Eur J Immunol 2004;34:3326-36.
29. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171:137-141.
30. Wythe SE, Dodd JS, Openshaw PJ, et al. OX40 ligand and programmed cell death 1 ligand 2 expression on inflammatory dendritic cells regulates CD4T cell cytokine production in the lung during viral disease. J Immunol 2012;188:1647-1655.
31. Tomassen P, Jarvis D, Newson R, et al. Staphylococcus aureus enterotoxin-specific IgE is associated with asthma in the general population: a GA(2)LEN study. Allergy 2013;68:1289-1297.
32. Maestrelli P, Schlunssen V, Mason P, et al. Contribution of host factors and workplace exposure to the outcome of occupational asthma. Eur Respir Rev 2012;21:88-96.
33. Farrell E, O'Connor TM, Duong M, et al. Circulating myeloid and plasmacytoid dendritic cells after allergen inhalation in asthmatic subjects. Allergy 2007;62:1139-1145.
34. Jahnsen FL, Moloney ED, Hogan T, et al. Rapid dendritic cell recruitment to the bronchial mucosa of patients with atopic asthma in response to local allergen challenge. Thorax 2001;56:823-826.
35. Lambrecht BN, Hammad H. Asthma: the importance of dysregulated barrier immunity. Eur J Immunol 2013;43:3125-3137.